Alpha 2.0
Login Register
» Authors » J Vencovsky

J Vencovsky

Explore the profile of J Vencovsky including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 69
Citations 1776
Followers 0
Related Specialties
Rheumatology
General Medicine
Physiology
Top 10 Co-Authors
K Pavelka
L Senolt
I E Lundberg
W E Ollier
R A Mageed
K Jarosova
J Gatterova
R N Maini
H Hulejova
S Ruzickova
Published In
Ann Rheum Dis
Cas Lek Cesk
Clin Exp Rheumatol
Physiol Res
Rheumatology (Oxford)
Affiliations
Soon will be listed here.
Recent Articles
1.
Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry
Tichy S, Nekvindova L, Baranova J, Vencovsky J, Pavelka K, Horak P, et al.
Scand J Rheumatol . 2024 Aug; 54(2):79-86. PMID: 39105330
Objectives: To compare the drug survival of etanercept to monoclonal tumour necrosis factor-α inhibitors in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Methods: Patients initiating first line biological therapy with...
2.
IL-40 is up-regulated in the synovial fluid and cartilage of osteoarthritis patients and contributes to the alteration of chondrocytes phenotype in vitro
Andres Cerezo L, Navratilova A, Kuklova M, Prokopcova A, Baloun J, Kropackova T, et al.
Arthritis Res Ther . 2024 Jul; 26(1):146. PMID: 39080724
Introduction: IL-40 is a novel cytokine associated with autoimmune connective tissue disorders such as rheumatoid arthritis (RA) or Sjögren syndrome. We have previously shown an accumulation of IL-40 in the...
3.
Circulating miRNAs in hand osteoarthritis
Baloun J, Pekacova A, Svec X, Kropackova T, Horvathova V, Hulejova H, et al.
Osteoarthritis Cartilage . 2022 Nov; 31(2):228-237. PMID: 36379393
Objective: Hand osteoarthritis (OA) is a frequent musculoskeletal disorder with an increasing prevalence during ageing. This study aimed to evaluate circulating microRNAs (miRNAs) in the plasma of patients with hand...
4.
Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis
Prajzlerova K, Komarc M, Forejtova S, Pavelka K, Vencovsky J, Senolt L, et al.
Physiol Res . 2021 Mar; 70(2):255-264. PMID: 33676382
Circulating miRNAs appear promising therapeutic and prognostic biomarkers. We aimed to investigate the predictive value of circulating miRNAs on the disease outcome following anti-TNF therapy in patients with ankylosing spondylitis...
5.
Altered dynamics of lipid metabolism in muscle cells from patients with idiopathic inflammatory myopathy is ameliorated by 6 months of training
Nemec M, Vernerova L, Laiferova N, Balazova M, Vokurkova M, Kurdiova T, et al.
J Physiol . 2020 Oct; 599(1):207-229. PMID: 33063873
Key Points: Regular exercise improves muscle functional capacity and clinical state of patients with idiopathic inflammatory myopathy (IIM). In our study, we used an in vitro model of human primary...
6.
Elevated Tenascin-C Serum Levels in Patients With Axial Spondyloarthritis
Bubova K, Prajzlerova K, Hulejova H, Gregova M, Mintalova K, Husakova M, et al.
Physiol Res . 2020 Jun; 69(4):653-660. PMID: 32584134
This study aimed to examine serum tenascin C (TNC) in different subsets of axial spondyloarthritis (axSpA) patients. Sixty-one patients fulfilling the Assessment of SpondyloArthritis international Society classification criteria for axSpA...
7.
Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis
Emery P, Suh C, Weinblatt M, Smolen J, Keystone E, Genovese M, et al.
Scand J Rheumatol . 2020 May; 49(5):361-370. PMID: 32468892
: SB4, SB2, and SB5 are biosimilars of etanercept (ETN), infliximab (INF), and adalimumab (ADA), respectively. This pooled analysis evaluated the immunogenicity of these treatments across three phase III randomized...
8.
Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients
Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper R, New R, et al.
J Autoimmun . 2019 Apr; 101:48-55. PMID: 30992170
Objectives: To determine prevalence and co-existence of myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs) and associated clinical characteristics in a large cohort of idiopathic inflammatory myopathy (IIM) patients....
9.
Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies
Ekholm L, Vosslamber S, Tjarnlund A, de Jong T, Betteridge Z, McHugh N, et al.
Scand J Immunol . 2016 May; 84(2):100-9. PMID: 27173897
Myositis is a heterogeneous group of autoimmune diseases, with different pathogenic mechanisms contributing to the different subsets of disease. The aim of this study was to test whether the autoantibody...
10.
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
Mariette X, Vencovsky J, Lortholary O, Gomez-Reino J, de Longueville M, Ralston P, et al.
RMD Open . 2015 Oct; 1(1):e000044. PMID: 26509064
Objectives: We report the incidence of tuberculosis (TB) across certolizumab pegol (CZP) clinical trials in rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), before and after the...